Evidence map›Paper›PMID 41640281›Full record

ArticleClinical transplantation2026

Ninety-Day Readmission and Morbidity Following Liver Transplantation for MASLD.

Zachary Leslie, Thomas Leventhal, Sean Nguyen, David Leishman, Cheyenna Espinoza, Eric Wise, Sayeed Ikramuddin, Raja Kandaswamy, Abraham J Matar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zachary LeslieCarleton College, Northfield, Minnesota, USA.
Thomas LeventhalDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.
Sean NguyenDepartment of Surgery, Division of Gastrointestinal/Bariatric Surgery, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0009-0008-9817-6819
David LeishmanDepartment of Surgery, Division of Gastrointestinal/Bariatric Surgery, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-7618-8132
Cheyenna EspinozaDepartment of Surgery, Division of Gastrointestinal/Bariatric Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Eric WiseDepartment of Surgery, Division of Gastrointestinal/Bariatric Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Sayeed IkramuddinDepartment of Surgery, Division of Gastrointestinal/Bariatric Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Raja KandaswamyDepartment of Surgery, Division of Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Abraham J MatarDepartment of Surgery, Division of Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-7351-7674

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe incidence of short-term (90-day) hospital readmission and morbidity following liver transplantation (LT) for metabolic dysfunction-associated steatotic liver disease (MASLD) is poorly characterized, and no study to date has distinguished these short-term outcomes between MASLD and non-MASLD LT recipients. The primary objective of this study was to leverage the National Readmissions Database (NRD) to distinguish 90-day readmission rates and morbidity among those undergoing LT for MASLD and non-MASLD etiologies.

methodsRecipients undergoing LT were identified in the NRD between January 1, 2016, and December 31, 2022. Morbidity was defined as an aggregate of common surgical complications. Univariate and age-sex adjusted quasi-Poisson regressions were used to identify trends and differences in characteristics for patients stratified by indication for LT. Multivariable logistic regression models were used to identify factors associated with 90-day readmissions and morbidity.

resultsA weighted total of 58 148 LT procedures were identified, of which 11 235 (19.3%) had MASLD etiology. LT for MASLD increased over the study period, while LT for hepatitis C and liver cancer decreased. Relative to non-MASLD LT recipients, MASLD LT recipients had increased comorbid risk profiles, including higher rates of class 3 obesity (body mass index [BMI] ≥ 40) and associated liver cancer. MASLD LT recipients had lower rates of 90-day readmission, morbidity, and cardiovascular complications (all p < 0.05). Among patients with class 3 obesity and liver cancer, MASLD etiology was associated with improved or non-inferior 90-day outcomes relative to non-MASLD LT recipients. Finally, among MASLD LT recipients, the presence of chronic kidney disease, prior bariatric surgery, dialysis, female sex, and chronic obstructive pulmonary disease were independent predictors of 90-day morbidity and readmission.

conclusionsDespite an increased comorbid risk profile, MASLD LT recipients had superior 90-day readmission rates and morbidity outcomes relative to non-MASLD LT recipients. MASLD etiology appears to normalize 90-day outcomes among patients with obesity and liver cancer.

Indexed as

Fatty LiverLiver TransplantationPatient ReadmissionPostoperative ComplicationsAdultFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedMorbidityPrognosisRetrospective StudiesRisk Factorsliver transplantationmetabolic dysfunction‐associated steatotic liver diseasemorbidityreadmission

Identifiers

PMID41640281
PMCPMC12873555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.